(Q34768663)

4 August 2017

1 reference

title

Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda (English)

1 reference

4 August 2017

0 references

visceral leishmaniasis

1 reference

1 reference

4 August 2017

Marleen Boelaert

0 references

Shyam Sundar

1 reference

4 August 2017

Piero Olliaro

1 reference

4 August 2017

Simon L Croft

1 reference

4 August 2017

Philippe Desjeux

series ordinal

1 reference

4 August 2017

Monique K Wasunna

series ordinal

1 reference

4 August 2017

Anthony D M Bryceson

series ordinal

1 reference

4 August 2017

publication date

1 August 2002

1 reference

Lancet Infectious Diseases

4 August 2017

published in

1 reference

4 August 2017

1 reference

4 August 2017

1 reference

4 August 2017

page(s)

494-501

1 reference

Leishmaniasis. Public health aspects and control

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

Socio-economics of visceral leishmaniasis in Bihar (India)

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

The reemergence of visceral leishmaniasis in Brazil

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

The epidemic of visceral leishmaniasis in western Upper Nile, southern Sudan: course and impact from 1984 to 1994.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

1 reference

7 January 2021

Prevalence and disease spectrum in a new focus of visceral leishmaniasis in Kenya

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

Malnutrition as a risk factor for severe visceral leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

HIV-associated visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

Endemic disease and development: the leishmaniases

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

Decreased sensitivity to meglumine antimoniate (Glucantime) ofLeishmania infantumisolated from dogs after several courses of drug treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

Protective efficacy of lambdacyhalothrin-impregnated bednets against Phlebotomus orientalis, the vector of visceral leishmaniasis in Sudan

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

Multi-centre evaluation of repeatability and reproducibility of the direct agglutination test for visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

Rapid accurate field diagnosis of Indian visceral leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

Development of a species-specific PCR assay for detection of Leishmania donovani in clinical samples from patients with kala-azar and post-kala-azar dermal leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

Polymerase chain reaction in the diagnosis and prognosis of Mediterranean visceral leishmaniasis in immunocompetent children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

Role of PCR in diagnosis and prognosis of visceral leishmaniasis in patients coinfected with human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

Electrocardiographic changes during treatment of leishmaniasis with pentavalent antimony (sodium stibogluconate)

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

A cluster of cases of severe cardiotoxicity among kala-azar patients treated with a high-osmolarity lot of sodium antimony gluconate

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

Clinical and experimental advances in treatment of visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

Current issues in the treatment of visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

Drug resistance in Indian visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

Evidence that the High Incidence of Treatment Failures in Indian Kala‐Azar Is Due to the Emergence of Antimony‐Resistant Strains ofLeishmania donovani

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

Practical guide for the treatment of leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

Visceral leishmaniasis unresponsive to antimonial drugs. I. Clinical and immunological studies.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

Investigation of the spread of human visceral leishmaniasis in central Tunisia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

Treatment of visceral leishmaniasis with amphotericin B colloidal dispersion

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome)

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

Influence of highly active antiretroviral therapy on the outcome of subclinical visceral leishmaniasis in human immunodeficiency virus-infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

Developments in the treatment of leishmaniasis and trypanosomiasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

Drug development for neglected diseases: a deficient market and a public-health policy failure

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

Trial of oral miltefosine for visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

Oral treatment of visceral leishmaniasis with miltefosine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

A policy for leishmaniasis with respect to the prevention and control of drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

Epidemic visceral leishmaniasis in southern Sudan: treatment of severely debilitated patients under wartime conditions and with limited resources

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

Aminosidine (paromomycin) in the treatment of leishmaniasis imported into the United Kingdom

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

Treatment of visceral leishmaniasis (kala-azar) with aminosidine (= paromomycin)-antimonial combinations, a pilot study in Bihar, India

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

Aminosidine plus sodium stibogluconate for the treatment of Indian kala-azar: a randomized dose-finding clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

Diagnostic PCR with Leishmania donovani specificity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

Operational validation of the direct agglutination test for diagnosis of visceral leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

Evaluation of the direct agglutination test (DAT) using freeze-dried antigen for the detection of anti-Leishmania antibodies in stored sera from various patient groups in Ethiopia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

Diagnosing visceral leishmaniasis with the recombinant K39 strip test: experience from the Sudan.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

Short report: detection of 72-75-kD and 123-kD fractions of Leishmania antigen in urine of patients with visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900347-X

7 January 2021

10.1016/S1473-3099(02)00347-X

Identifiers

DOI

1 reference

4 August 2017

1 reference